Added to YB: 2026-06-24
Pitch date: 2026-06-21
ABVX [neutral]
ABIVAX Société Anonyme
Author Info
Alpha Talon Investment Research is a Hong Kong–based private family office deploying only proprietary capital across biotech, value turnarounds, and catalyst-driven shorts, focused on intrinsic value, regulatory odds, and mispriced fundamentals. Sign up for the newsletter.
Company Info
ABIVAX Société Anonyme, a clinical-stage biotechnology company, develops therapeutics that harness the body’s natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases.
Market Cap
EUR 6.8B
Pitch Price
N/A
Price Target
N/A
Dividend
N/A
EV/EBITDA
-25.23
P/E
-18.96
EV/Sales
1.3K
Sector
Biotechnology
Category
special_situation
ABIVAX (ABVX): Thesis Stress-Test After the Drawdown — Efficacy Still Shines, but Safety Optics Now Drive the Multiple
ABVX (update): UC biotech re-centered on safety after ~45% drawdown. Obefazimod Ph3 ABTECT maintenance Wk44 remission 50.8%/51.3% (25/50mg) vs 10.4% placebo (p<0.0001)—efficacy strong. Selloff on malignancy optics (mostly 50mg arm). €491.6M cash, runway into Q4 2027, FY25 burn €161M. Multiple now hinges on FDA labeling/dose selection vs takeout optionality.
Read full article (4 min)